Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy

The purpose of this study is as follows: 1. Determine whether people receiving the combination treatment of olutasidenib, venetoclax, and azacitidine have the same, more, or fewer side effects compared to the usual chemotherapy treatment that people with this condition receive. 2. Determine how well the combination treatment of olutasidenib, venetoclax, and azacitidine works compared to the usual chemotherapy treatment that people with this condition receive.

Trial Details

NCT ID
NCT06782542
Phase
PHASE2
Sponsor
Justin Watts, MD
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Olutasidenib
  • Venetoclax
  • Azacitidine
Locations (sample)
  • Miami, Florida, United States|25.77427,-80.19366

Key Eligibility Criteria

  • Participant is an adult male or female participant aged 18-75 years considered eligible to undergo intensive induction chemotherapy at the time of …
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2
  • Confirmed diagnosis of:
  • Newly diagnosed AML Isocitrate dehydrogenase 1 (IDH1) R132 mutated disease as assessed locally. Note: historical results from within 30 days of inf…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →